Galectin Therapeutics Inc.
GALT
$2.41
$0.010.42%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 41.91% | 34.46% | 17.25% | 8.91% | -10.14% |
| Total Depreciation and Amortization | 44.74% | 43.24% | -38.89% | -11.43% | 280.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 150.97% | 112.88% | 1.57% | -23.79% | -39.37% |
| Change in Net Operating Assets | -85.46% | -73.34% | -69.30% | -79.39% | 75.02% |
| Cash from Operations | 46.31% | 42.84% | 9.07% | -8.67% | -8.97% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 5.00% | -30.00% | -72.50% | -30.00% | -33.33% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 367.16% | 346.21% | 987.50% | -73.17% | -87.77% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 25.93% | -15.22% | -62.63% | -41.12% | -46.98% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 141.43% | 124.67% | -331.93% | -254.97% | -380.13% |